{"id":"NCT04026412","sponsor":"Bristol-Myers Squibb","briefTitle":"A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery","officialTitle":"A Phase 3, Randomized, Open Label Study to Compare Nivolumab Plus Concurrent Chemoradiotherapy (CCRT) Followed by Nivolumab Plus Ipilimumab or Nivolumab Plus CCRT Followed by Nivolumab vs CCRT Followed by Durvalumab in Previously Untreated, Locally Advanced Non-small Cell Lung Cancer (LA NSCLC)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-10-08","primaryCompletion":"2024-03-22","completion":"2024-11-26","firstPosted":"2019-07-19","resultsPosted":"2025-07-24","lastUpdate":"2025-07-24"},"enrollment":925,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Non-Small Cell Lung Cancer (NSCLC)"],"interventions":[{"type":"BIOLOGICAL","name":"nivolumab","otherNames":[]},{"type":"BIOLOGICAL","name":"ipilimumab","otherNames":[]},{"type":"BIOLOGICAL","name":"durvalumab","otherNames":[]}],"arms":[{"label":"Arm A: nivolumab + CCRT + ipilimumab","type":"EXPERIMENTAL"},{"label":"Arm B: nivolumab + CCRT","type":"EXPERIMENTAL"},{"label":"Arm C: CCRT + durvalumab","type":"EXPERIMENTAL"}],"summary":"The primary purpose of the study is to compare the effectiveness of nivolumab plus concurrent chemoradiotherapy (CCRT) followed by nivolumab plus ipilimumab vs CCRT followed by durvalumab in participants with untreated Locally Advanced Non-small Cell Lung Cancer (LA NSCLC).","primaryOutcome":{"measure":"Arm A Vs Arm C - Progression-Free Survival (PFS) by RECIST 1.1 Per Blinded Independent Central Review (BICR)","timeFrame":"From randomization untill disease progression or death, whichever occurs first (up to approximately 53 months)","effectByArm":[{"arm":"Arm A:Nivo + CCRT/Nivo + Ipi","deltaMin":16.69,"sd":null},{"arm":"Arm C: CCRT/Durva","deltaMin":15.64,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.6460"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":4},"locations":{"siteCount":183,"countries":["United States","Argentina","Australia","Belgium","Brazil","Canada","Chile","China","France","Germany","Greece","Ireland","Italy","Japan","Mexico","Netherlands","Poland","Puerto Rico","Romania","Russia","Singapore","South Korea","Spain","Sweden","Switzerland","Taiwan","United Kingdom"]},"refs":{"pmids":["34489161"],"seeAlso":["https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html","http://www.BMSClinicalTrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":180,"n":282},"commonTop":["Anaemia","Nausea","Cough","Constipation","Oesophagitis"]}}